Abstract SS02-02: Chemoprevention: Poised for Success

Phase III trials demonstrated that chemoprevention was effective in reducing the risk of breast, prostate, and colorectal cancers, warranting further research and education. The FDA approved raloxifene in 2007 to reduce breast cancer risk in high-risk post-menopausal women, adding to the previously approved tamoxifen. The Prostate Cancer Prevention Trial found that finasteride reduced prostate cancer risk by 25% over 7 years, with subsequent studies alleviating concerns about high-grade cancers. Additionally, a combination of DFMO and sulindac prevented 70% of colon polyps and 92% of advanced adenomas. These findings highlighted the potential of chemoprevention in significantly lowering cancer risks, emphasizing the need for expanded research and collaboration in this field.